Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

How is Xpert MTB/RIF being implemented in 22 high tuberculosis burden countries?

Zhi Zhen Qin, Madhukar Pai, Wayne Van Gemert, Suvanand Sahu, Marzieh Ghiasi, Jacob Creswell
European Respiratory Journal 2014; DOI: 10.1183/09031936.00147714
Zhi Zhen Qin
1McGill International TB Centre, and Dept of Epidemiology and Biostatistics, McGill University, Montreal, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Madhukar Pai
1McGill International TB Centre, and Dept of Epidemiology and Biostatistics, McGill University, Montreal, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wayne Van Gemert
2Global TB Progamme, World Health Organization, Geneva, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suvanand Sahu
3Stop TB Partnership, Geneva, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marzieh Ghiasi
1McGill International TB Centre, and Dept of Epidemiology and Biostatistics, McGill University, Montreal, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacob Creswell
3Stop TB Partnership, Geneva, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: creswellj@stoptb.who.int
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Extract

To the Editor:

Accurate and rapid diagnosis is crucial for tuberculosis control by ensuring a timely start to treatment and reducing transmission. In 2012, almost one third of tuberculosis cases were not diagnosed and/or reported to national tuberculosis programmes (NTPs), and <25% of estimated incident multidrug-resistant (MDR) cases were diagnosed [1]. Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA), a nucleic acid amplification test, was recommended in 2010 by the World Health Organization (WHO) for detection of HIV-associated pulmonary tuberculosis and rifampicin resistance [2]. In 2013, the test was recommended for detection of paediatric tuberculosis and some forms of extrapulmonary tuberculosis (EPTB), as well as an initial test to replace smear microscopy [3].

Following these recommendations, modules and cartridges have been procured in increasing numbers. As of June 30, 2014, 15 846 Xpert modules and 7.5 million cartridges were procured by 104 countries at concessional prices [4], yet the potential market is much larger [5]. Although general policies regarding Xpert in the 22 high-burden countries (HBCs) have been summarised [1] and some experiences from early Xpert implementers are available [6,7], a more comprehensive analysis of NTPs’ policies and implementation of Xpert has not been performed.

To assess the current landscape of implementation of Xpert, we designed a

  • Received August 12, 2014.
  • Accepted October 6, 2014.
  • ©ERS
Next
Back to top
Vol 61 Issue 3 Table of Contents
European Respiratory Journal: 61 (3)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
How is Xpert MTB/RIF being implemented in 22 high tuberculosis burden countries?
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
How is Xpert MTB/RIF being implemented in 22 high tuberculosis burden countries?
Zhi Zhen Qin, Madhukar Pai, Wayne Van Gemert, Suvanand Sahu, Marzieh Ghiasi, Jacob Creswell
European Respiratory Journal Jan 2014, erj01477-2014; DOI: 10.1183/09031936.00147714

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
How is Xpert MTB/RIF being implemented in 22 high tuberculosis burden countries?
Zhi Zhen Qin, Madhukar Pai, Wayne Van Gemert, Suvanand Sahu, Marzieh Ghiasi, Jacob Creswell
European Respiratory Journal Jan 2014, erj01477-2014; DOI: 10.1183/09031936.00147714
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis
  • A rare pulmonary zygomycosis manifested as chronic mediastinitis and bronchial perforation
  • Pulmonary endarterectomy in sickle cell haemoglobin C disease
Show more Letter

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society